Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria.

Kristoffersson AN, Bissantz C, Okujava R, Haldimann A, Walter I, Shi T, Zampaloni C, Nielsen EI.

J Antimicrob Chemother. 2019 Oct 31. pii: dkz440. doi: 10.1093/jac/dkz440. [Epub ahead of print]

PMID:
31670804
2.

Erratum to: Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.

Thorsted A, Kristoffersson AN, Maarbjerg SF, Schrøder H, Wang M, Brock B, Nielsen EI, Friberg LE.

J Antimicrob Chemother. 2019 Oct 25. pii: dkz429. doi: 10.1093/jac/dkz429. [Epub ahead of print] No abstract available.

PMID:
31650174
3.

Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.

Thorsted A, Kristoffersson AN, Maarbjerg SF, Schrøder H, Wang M, Brock B, Nielsen EI, Friberg LE.

J Antimicrob Chemother. 2019 Oct 1;74(10):2984-2993. doi: 10.1093/jac/dkz270.

PMID:
31273375
4.

Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?

Andersen MG, Thorsted A, Storgaard M, Kristoffersson AN, Friberg LE, Öbrink-Hansen K.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02306-17. doi: 10.1128/AAC.02306-17. Print 2018 May.

5.

Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations.

Brill MJE, Kristoffersson AN, Zhao C, Nielsen EI, Friberg LE.

Clin Microbiol Infect. 2018 Jul;24(7):697-706. doi: 10.1016/j.cmi.2017.11.023. Epub 2017 Dec 8. Review.

6.

Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli.

Khan DD, Lagerbäck P, Malmberg C, Kristoffersson AN, Wistrand-Yuen E, Sha C, Cars O, Andersson DI, Hughes D, Nielsen EI, Friberg LE.

Int J Antimicrob Agents. 2018 Mar;51(3):399-406. doi: 10.1016/j.ijantimicag.2017.10.019. Epub 2017 Nov 7.

PMID:
29127049
7.

Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.

Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar Y, Altunin S, Paul M; AIDA consortium.

BMJ Open. 2016 Apr 20;6(4):e009956. doi: 10.1136/bmjopen-2015-009956.

8.

Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.

Mohamed AF, Kristoffersson AN, Karvanen M, Nielsen EI, Cars O, Friberg LE.

J Antimicrob Chemother. 2016 May;71(5):1279-90. doi: 10.1093/jac/dkv488. Epub 2016 Feb 4.

PMID:
26850719
9.

Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.

Kristoffersson AN, David-Pierson P, Parrott NJ, Kuhlmann O, Lave T, Friberg LE, Nielsen EI.

Pharm Res. 2016 May;33(5):1115-25. doi: 10.1007/s11095-016-1856-x. Epub 2016 Jan 19.

PMID:
26786016
10.

Inter occasion variability in individual optimal design.

Kristoffersson AN, Friberg LE, Nyberg J.

J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):735-50. doi: 10.1007/s10928-015-9449-6. Epub 2015 Oct 1.

Supplemental Content

Loading ...
Support Center